Metabolomic Pathway Analysis of Schizophrenic Brains
Researchers from the Japanese Institute of Neuroscience have identified differences in the low-molecular-weight metabolite profiles of the brains of schizophrenia patients using CE–TOF-MS.
Photo Credit: Lisa Alisa/Shutterstock.com
Researchers from the Japanese Institute of Neuroscience, Tokyo, Japan, have identified differences in the low-molecular-weight metabolite profiles of the brains of schizophrenia patients using capillary electrophoresis time-of-flight mass spectrometry (CE–TOF-MS) (1).
Affecting more than 21 million people worldwide, schizophrenia is a complex mental disorder characterized by profound disruptions in thinking, affecting language, perceptions, and the sense of self (2). While effective treatments for schizophrenia exist, the causes of schizophrenia are still not entirely understood.
Morphological and functional alterations to specific brain regions have been suggested as a cause, with volume reductions in the frontal and temporal lobes of schizophrenia patients being supported by previous imaging studies (1). Previous metabolomic studies have also identified 10 metabolites that differ significantly in the brains of schizophrenics when compared to control brain samples. However, the specific alterations in the profiles of low-molecular-weight metabolites and the metabolic pathways that have been altered in the brains of schizophrenia patients are still poorly understood. To address this researchers used CE–TOF-MS to analyze frontal cortex and hippocampus brain samples from schizophrenia patients and compared these to controls.
In total, 294 metabolites were identified in the frontal cortex and 280 were identified in the hippocampus. Dipeptide glycylglycine was found to be significantly increased in both investigated regions. Pathway analysis led researchers to believe this significant increase may be a result of increased proteolysis within schizophrenic brains. Increased lactic acid levels were also found, which researchers believe indicates an altered glucose metabolism.
References
- T. Fujii et al., Schizophrenia Res.183, 70–74 (2017).
- http://www.who.int/mental_health/management/schizophrenia/en/
2024 EAS Awardees Showcase Innovative Research in Analytical Science
November 20th 2024Scientists from the Massachusetts Institute of Technology, the University of Washington, and other leading institutions took the stage at the Eastern Analytical Symposium to accept awards and share insights into their research.
Inside the Laboratory: The Richardson Group at the University of South Carolina
November 20th 2024In this edition of “Inside the Laboratory,” Susan Richardson of the University of South Carolina discusses her laboratory’s work with using electron ionization and chemical ionization with gas chromatography–mass spectrometry (GC–MS) to detect DBPs in complex environmental matrices, and how her work advances environmental analysis.
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
Infographic: Be confidently audit ready, at any time and reduce failures in pharma QC testing
November 20th 2024Discover how you can simplify the audit preparation process with data integrity dashboards that provide transparency to key actions, and seamlessly track long-term trends and patterns, helping to prevent system suitability failures before they occur with waters_connect Data Intelligence software.
Critical Role of Oligonucleotides in Drug Development Highlighted at EAS Session
November 19th 2024A Monday session at the Eastern Analytical Symposium, sponsored by the Chinese American Chromatography Association, explored key challenges and solutions for achieving more sensitive oligonucleotide analysis.
